ALEXANDRIA, Va., March 26 -- United States Patent no. 12,257,291, issued on March 25, was assigned to Crosswalk Therapeutics Inc. (Cambridge, Mass.).
"Human alpha-galactosidase variants" was invented by Nicholas J. Agard (San Francisco), Mathew G. Miller (San Carlos, Calif.), Xiyun Zhang (Fremont, Calif.) and Gjalt W. Huisman (Redwood City, Calif.).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pHgreater than4.5) and basic (pHless than7) conditions. The invention also relates to the ...